KME 0584
Alternative Names: KME-0584Latest Information Update: 29 Feb 2024
At a glance
- Originator Cincinnati Children's Hospital Medical Center; National Center for Advancing Translational Sciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Interleukin-1 receptor-associated kinase inhibitors; IRAK4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Myelodysplastic syndromes; Unspecified
Most Recent Events
- 16 Feb 2024 US FDA approves IND application for KME 0584 in Acute myeloid leukemia and Myelodysplastic syndromes
- 31 Jan 2024 KME 0584 is available for licensing as of 31 Jan 2024. https://www.kurometherapeutics.com/partnering/ (Kurome Therapeutics website, January 2024)
- 31 Jan 2024 Preclinical trials in Unspecified in USA (unspecified route) before January 2024 (Kurome Therapeutics pipeline, January 2024)